The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
BOREAS: Efficacy and safety of navtemadlin in JAKi R/R MF
|
Navtemadlin is a potent, selective, oral MDM2 inhibitor that restores p53 function.1 Results from the phase III BOREAS trial (NCT03662126) evaluating the safety and efficacy of navtemadlin vs BAT in 183 patients with TP53wt MF who were R/R to JAK inhibitors were presented by John Mascarenhas at the 66th ASH Annual Meeting and Exposition.1 |
| Key learnings |
| At Week 24, the SVR35 assessed by central review MRI/CT (15% vs 5%), driver gene VAF reduction (21% vs 12%), and BM fibrosis (47% vs 24%) were higher with navtemadlin monotherapy compared with BAT. |
| TSS50 at Week 24 (24% vs 12%; p = 0.0507) and absolute change in TSS at Week 24 (p = 0.0078) were higher with navtemadlin monotherapy compared with BAT. |
| Thrombocytopenia (37% vs 25%), anemia (29% vs 28%), neutropenia (25% vs 12%), diarrhea (6% vs 2%), nausea (4% vs 0%), and vomiting (2% vs 0%) were the most frequent Grade 3 or 4 hematologic and GI TEAEs with navtemadlin and BAT, respectively. |
| These findings demonstrate that navtemadlin monotherapy is effective, with an acceptable safety profile and disease-modifying potential, and warrants further studies investigating navtemadlin in MF. |
Abbreviations: BAT, best available therapy; BM, bone marrow; CT. computed tomography; GI, gastrointestinal; JAKi, Janus kinase inhibitor; MF, myelofibrosis; MRI, magnetic resonance imaging; R/R relapsed/refractory; SVR35; spleen volume reduction ≥35%; TSS50, total symptom score reduction ≥50%; VAF, variant allele frequency; WT, wild-type.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
